AMP kinase | AMPK subfamily | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

AMP kinase

Target not currently curated in GtoImmuPdb

Target id: 1540

Nomenclature: AMP kinase

Abbreviated Name: AMPK

Family: AMPK subfamily

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Previous and Unofficial Names
AMP-activated protein kinase
Database Links
KEGG Enzyme
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Structure of full length human AMPK in complex with a small molecule activator, a thienopyridone derivative (A-769662)
Ligand:  A-769662
Resolution:  3.92Å
Species:  Human
References:  11
Enzyme Reaction
EC Number:

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
A-769662 Rn Activation 6.2 – 6.9 pEC50 2,5
pEC50 6.9 (EC50 1.16x10-7 M) [5]
Description: Activation of AMPK purified from rat liver, which contains α1 and α2 catalytic subunits, with β1 and γ1 regulatory subunits.
pEC50 6.2 (EC50 7x10-7 M) [2]
Description: Activation of baculovirus expressed α1,β1,&gamma1 recombinant isoform of AMPK.
A-769662 Hs Activation 6.0 pEC50 2
pEC50 6.0 (EC50 1.1x10-6 M) [2]
Description: Activation of AMPK partially purified from HEK cells.
adenosine 5'-monophosphate Hs Activation 4.2 pEC50 2
pEC50 4.2 (EC50 6.1x10-5 M) [2]
Description: Activation of AMPK partially purified from HEK cells.
acadesine Hs Activation - - 3
View species-specific activator tables
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
cerdulatinib Hs Inhibition 8.2 pIC50 1
pIC50 8.2 (IC50 6x10-9 M) [1]
compound 13a [PMID: 23639540] Hs Inhibition 7.4 pIC50 4
pIC50 7.4 (IC50 3.99x10-8 M) [4]
dorsomorphin Hs Inhibition 7.4 pIC50 6
pIC50 7.4 (IC50 4.1x10-8 M) [6]
Description: Assayed using AMPK heterotrimeric complex containing α2, β1, γ1 subunits
General Comments
AMP-activated protein kinase (AMPK) is a heterotrimeric protein kinase, made up of one catalytic α subunit, one β and one γ subunit, both of which are regulatory in function. AMPK is a regulator of energy balance at the cellular and whole body levels. AMP binds to "Bateman domains" on the γ subunit and this promotes activation via increased phosphorylation of Thr172 on the activation loop of AMPK's α subunit. Characterization of functional, full-length, muscle-specific α2β2γ3 AMPK produced in E. coli has been reported [7].
AMPK was originally recognised as a regulator of energy and metabolic balance and was proposed as a promising target for drugs aimed at treatment of type 2 diabetes and the metabolic syndrome. It has subsequently been ascribed roles in additional biological processes. For example, AMPK is now considered as a driver of autophagy, a process that is very important for maintaining proper cell function. The autophagic system degrades unwanted or damaging cellular contents including long-lived proteins, protein complexes, damaged organelles and invading pathogens. Dysregulated/ineffective autophagy is recognised as being associated with a variety of diseases including cancer, viral and bacterial infections, and neurodegeneration. In neurodegenerative conditions that are characterised by the formation of protein aggregates (tauopathies, Huntington disease, Alzheimer's), autophagic function is considered to be key for effective depletion of the aberrant proteins whose accumulation proves to be toxic to cells. Thus, drug-like AMPK activators are being investigated as a mechanism to elevate autophagy-driven clearance of the protein aggregates associated with neurodegenerative diseases [10], as an alternative mechanism to mTOR inhibition [8-9].


Show »

1. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U. (2014) The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J. Pharmacol. Exp. Ther., 351 (3): 538-48. [PMID:25253883]

2. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R et al.. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab., 3 (6): 403-16. [PMID:16753576]

3. Corton JM, Gillespie JG, Hawley SA, Hardie DG. (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem., 229 (2): 558-65. [PMID:7744080]

4. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. (2013) Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg. Med. Chem. Lett., 23 (11): 3248-52. [PMID:23639540]

5. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, Sakamoto K. (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem., 282 (45): 32549-60. [PMID:17855357]

6. Machrouhi F, Ouhamou N, Laderoute K, Calaoagan J, Bukhtiyarova M, Ehrlich PJ, Klon AE. (2010) The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity. Bioorg. Med. Chem. Lett., 20 (22): 6394-9. [PMID:20932747]

7. Rajamohan F, Harris MS, Frisbie RK, Hoth LR, Geoghegan KF, Valentine JJ, Reyes AR, Landro JA, Qiu X, Kurumbail RG. (2010) Escherichia coli expression, purification and characterization of functional full-length recombinant alpha2beta2gamma3 heterotrimeric complex of human AMP-activated protein kinase. Protein Expr. Purif., 73 (2): 189-97. [PMID:20451617]

8. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ et al.. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet., 36 (6): 585-95. [PMID:15146184]

9. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet., 17 (2): 170-8. [PMID:17921520]

10. Walter C, Clemens LE, Müller AJ, Fallier-Becker P, Proikas-Cezanne T, Riess O, Metzger S, Nguyen HP. (2016) Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro. Neuropharmacology, 108: 24-38. [PMID:27133377]

11. Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, Patel BR, Heath RB, Walker PA, Hallen S et al.. (2013) Structural basis of AMPK regulation by small molecule activators. Nat Commun, 4: 3017. [PMID:24352254]

How to cite this page

AMPK subfamily: AMP kinase. Last modified on 07/09/2018. Accessed on 04/07/2020. IUPHAR/BPS Guide to PHARMACOLOGY,